Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk -study

Reuters - 21/09/2020 - Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on Saturday. The drug combination also doubled patients' median length of time before their cancer began to worsen to 16.6 months compared to progression-free survival of 8.3 months for patients treated with the chemotherapy sunitinib, an older Pfizer Inc drug sold under the brand name Sutent. "There is no doubt in my mind that this will be a major player" as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Choueiri from Dana-Farber Cancer Institute in Boston. He noted that the oncology community is already familiar with both drugs and that the combination demonstrated positive results on all the study's goals. The Phase III study of 651 patients with a...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 21 September, 202029 September, 2020